CN113117013A - Composition for improving climacteric syndrome and preparation method thereof - Google Patents
Composition for improving climacteric syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN113117013A CN113117013A CN201911392903.8A CN201911392903A CN113117013A CN 113117013 A CN113117013 A CN 113117013A CN 201911392903 A CN201911392903 A CN 201911392903A CN 113117013 A CN113117013 A CN 113117013A
- Authority
- CN
- China
- Prior art keywords
- parts
- angelica
- climacteric syndrome
- medlar
- rhizoma anemarrhenae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 14
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 13
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 13
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 10
- 241000405414 Rehmannia Species 0.000 claims abstract description 10
- 235000011438 Albizia odoratissima Nutrition 0.000 claims abstract description 9
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 6
- 244000061520 Angelica archangelica Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000220433 Albizia Species 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 240000007185 Albizia julibrissin Species 0.000 claims 1
- 241000605447 Anemarrhena Species 0.000 claims 1
- 241000213006 Angelica dahurica Species 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000015468 Lycium chinense Nutrition 0.000 claims 1
- 229930191283 anemarrhena Natural products 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 240000000559 Albizia odoratissima Species 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 210000003734 kidney Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000125175 Angelica Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical group C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 2
- 241000382455 Angelica sinensis Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to a composition containing prepared rhizome of rehmannia, angelica, rhizoma anemarrhenae, glossy privet fruit, medlar, dwarf lilyturf tuber, spina date seed and albizia flower and having the function of improving climacteric syndrome and a preparation method thereof. The composition provided by the invention is obviously superior to the singly used radix rehmanniae preparata, angelica, rhizoma anemarrhenae, glossy privet fruit, medlar, radix ophiopogonis, spina date seed and albizia flower in the aspect of improving the climacteric syndrome, and has a synergistic effect.
Description
Technical Field
The invention relates to a functional food or a health-care food, in particular to a composition containing prepared rhizome of rehmannia, angelica, rhizoma anemarrhenae, glossy privet fruit, medlar, dwarf lilyturf tuber, spina date seed and albizia flower and having the function of improving climacteric syndrome and a preparation method thereof.
Background
Climacteric Syndrome (CS) is mostly caused by age 45-55, and a series of symptoms mainly including autonomic nervous system dysfunction, nerve dysfunction, hot flashes, sweating, sleep disorder, paraesthesia, mood fluctuation and the like caused by sex hormone fluctuation or reduction before and after menopause of women.
Modern western medicine believes that the menopause is caused mainly by the change of the ovarian secretory function, which leads to the change of the internal environment of the body, the treatment mode of the disease is generally sex Hormone Therapy (HT), the treatment effect is not good, if the Hormone is not used properly, many side effects such as uterine bleeding, malignant change of target organs and the like are brought, and many people cannot accept the treatment mode.
Compared with western medicine treatment, the traditional Chinese medicine treatment has the advantages of integral regulation and less side effects, and can better improve the symptoms of the climacteric syndrome and improve the life quality of patients with the climacteric syndrome. Modern Chinese medicine considers that the whole disease can be summarized as deficiency of kidney yin, and deficiency of heart, liver and spleen, and the disease presents the characteristic of symptom group of deficiency-middle-excess. Therefore, nourishing yin and tonifying kidney is the main method for improving climacteric syndrome.
The radix rehmanniae Preparata is root tuber of rehmannia glutinosa Libosch of Scrophulariaceae, also called radix rehmanniae Preparata or dried rehmannia root, has sweet taste and mild nature, and enters liver and kidney meridians. Has effects of replenishing blood and nourishing yin, and can be used for treating blood deficiency and chlorosis, giddiness, cardiopalmus and insomnia, menoxenia, metrorrhagia, etc., and can also be used for treating hectic fever and bone steaming due to kidney yin deficiency, night sweat, spermatorrhea, diabetes, etc.
Angelica sinensis is root of Angelica sinensis of Umbelliferae, sweet, pungent and warm in nature, and enters liver, heart and spleen meridians. Has effects in replenishing blood, promoting blood circulation, regulating menstruation, and relieving pain. It is commonly used for blood deficiency, sallow complexion, vertigo, palpitation, irregular menstruation, amenorrhea, dysmenorrhea, and abdominal pain due to deficiency cold. For example, it is used with Dang Gui and Shu Di Huang to treat blood deficiency, vertigo, palpitation, insomnia, irregular menstruation, metrorrhagia, metrostaxis and metrostaxis, such as in the classic formula Siwu Tang.
Anemarrhena asphodeloides bunge is a perennial herb, also called Shen, bitter and cold in nature, and enters lung, stomach and kidney meridians. Has effects of nourishing yin and lowering fire. It is commonly indicated for hectic fever, night sweat, restlessness and other symptoms due to yin deficiency with effulgent fire and lung and kidney deficiency. For bone-steaming tidal fever due to yin deficiency, it is combined with Zhi mu and Di Huang, for example, Da Bu Yin Wan from Dan xi Xin Fa.
Fructus Ligustri Lucidi is fruit of Ligustrum lucidum belonging to Oleaceae, and has bitter, sweet and neutral properties, and enters lung, liver and kidney meridians. Has effects of nourishing liver and kidney. It is recorded in Ben Cao Zheng (materia medica treatment), fructus Ligustri Lucidi has effects of nourishing yin qi, suppressing yin fire, relieving restlessness, heat, steaming bone, relieving deficiency sweat, quenching thirst, and treating stranguria with turbid urine, metrorrhagia, hematochezia, hematuria, yin sore, and anal fistula pain. The book Ben Cao Xin (herbal remedy) also records that the medicine has the efficacies of nourishing yin, tonifying the kidney, tonifying qi and soothing the liver, and is commonly used for treating lumbocrural pain, stimulating the menstrual flow and regulating the blood.
The medlar is a fruit of plant medlar, has been taken for thousands of years in China, and is the most common medicine-food dual-purpose Chinese medicinal material. Sweet and neutral in nature, and has the effects of nourishing liver, nourishing kidney and moistening lung. The medlar is rich in medlar polysaccharide, betaine, medlar pigment and other components, has the efficacies of immunoregulation, aging resistance, tumor resistance, free radical removal, fatigue resistance, radiation resistance, liver protection, reproductive function protection and improvement and the like, is often used together with the rehmannia glutinosa and the angelica, and has good effects of nourishing yin, tonifying the kidney, invigorating qi and enriching the blood.
The dwarf lilyturf tuber is slightly cold in nature, sweet and slightly bitter in taste, enters stomach, lung and heart channels, and has the effects of nourishing yin, moistening lung, tonifying stomach, promoting fluid production, clearing heart fire and relieving restlessness. It is often used for dry cough due to lung dryness, tuberculosis due to yin deficiency, thirst due to body fluid consumption, diabetes due to internal heat, vexation, insomnia, and constipation due to intestinal dryness. In addition, radix Ophiopogonis has effects of tranquilizing, hypnotizing, resisting arrhythmia, etc., and especially has many effects on promoting health of climacteric women.
Suan Zao ren is sweet and sour in nature and neutral in nature, entering heart, liver and gallbladder meridians. Has effects in nourishing heart, benefiting liver, tranquilizing mind, and arresting sweating. The earliest Chinese book, Shennong Ben Cao Jing, records: all the actions of Zi Su Zao are to tonify liver, strengthen tendons and bones and help yin qi. It is recorded in the book Ben Cao gang mu of Li Shi Zhen of the Ming Dynasty, the Zi ren is used for treating insomnia due to gallbladder deficiency and polydipsia and sweating due to deficiency; unprocessed herbs for gallbladder heat and good sleep are also indicated for Jueyin shaoyang herbs. Spina date seed has good treatment effect on symptoms such as dysphoria, insomnia, palpitation, polydipsia, sweating due to debility and the like, and is a common medicine in a formula for treating poor sleep quality of climacteric women.
Flos Albizziae is dry inflorescence of Albizziae of Leguminosae, has mild nature and bitter taste, enters heart and spleen channels, has effects of nourishing yin and tonifying yang, relieving depression, regulating qi-flowing, tranquilizing mind, and activating collaterals, and is used for treating liver depression and chest distress, melancholy and malaise, amnesia and insomnia caused by heart kidney imbalance.
Disclosure of Invention
The invention aims to provide a composition for improving climacteric syndrome and application thereof.
The invention adopts the following technical scheme to achieve the purpose.
A composition for improving climacteric syndrome comprises the following components in parts by weight: 10-30 parts of prepared rhizome of rehmannia, 5-15 parts of angelica, 10-25 parts of rhizoma anemarrhenae, 10-25 parts of glossy privet fruit, 10-35 parts of medlar, 5-15 parts of radix ophiopogonis, 5-20 parts of spina date seed and 10-30 parts of albizia flower.
Preferably, the composition for improving the climacteric syndrome comprises the following components in parts by weight: 12-25 parts of prepared rhizome of rehmannia, 6-12 parts of angelica, 11-20 parts of rhizoma anemarrhenae, 15-20 parts of glossy privet fruit, 11-28 parts of medlar, 5-13 parts of radix ophiopogonis, 7-15 parts of spina date seed and 10-20 parts of albizia flower.
Further preferably, the composition for improving the climacteric syndrome comprises the following components in parts by weight: 16 parts of prepared rhizome of rehmannia, 8 parts of angelica, 13 parts of rhizoma anemarrhenae, 18 parts of glossy privet fruit, 15 parts of medlar, 8 parts of dwarf lilyturf tuber, 10 parts of spina date seed and 12 parts of albizia flower.
The preparation method comprises the following steps: pulverizing radix rehmanniae Preparata, radix Angelicae sinensis, rhizoma anemarrhenae and semen Ziziphi Spinosae into coarse powder, extracting with 10 times of 75% ethanol for 3 times (1 hr each time), mixing extractive solutions, filtering, and concentrating the filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of about 1.20; extracting fructus Ligustri Lucidi, fructus Lycii, radix Ophiopogonis, and flos Albizziae with 10 times of water for 3 times, each for 1 hr, mixing extractive solutions, filtering, concentrating the filtrate at 80 deg.C under reduced pressure to obtain soft extract with relative density of 1.20, mixing with the above soft extract, drying at 80 deg.C under reduced pressure, pulverizing, adding 4% binder (95% ethanol, 4% of the total weight of other components) and adjuvants, making into soft mass, granulating, drying, grading, and making into granule or other dosage forms.
In the above composition:
the weight parts can be the weight units known in the medical field such as mu g, mg, g, kg, and the like, and can also be multiples thereof such as 1/10, 1/100, 10, 100, and the like.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The used medicinal materials such as radix rehmanniae Preparata, radix Angelicae sinensis, rhizoma anemarrhenae, fructus Ligustri Lucidi, fructus Lycii, radix Ophiopogonis, semen Ziziphi Spinosae, and flos Albizziae are purchased from Beijing Tongrentang pharmacy.
In the preparation process of the invention, the used means are all conventional technical means in the field unless otherwise specified.
1 animal experiment.
1.1 test subject
Female SD rats 84, 12 weeks old, weighing 275 ± 20g, of which 12 were sham operated groups; the remaining 72 female rats, which were successfully molded (ovariectomized), were provided by the institute for laboratory animals, military medical sciences, national liberation force.
1.2 administration by groups
The 72 rats successfully modelled were randomly divided into 6 groups of 12 rats each, namely, castration group, composition low dose (2.5 g/kg) group, medium dose (5.0 g/kg) group, high dose (10.0 g/kg) group, estradiol valerate group (0.00009 g/kg) and climacteric syndrome group (0.48 g/kg); another 12 sham-operated female rats were the sham-operated group. The rats in each group are subjected to intragastric administration for 1 time per day according to the intragastric administration amount of 10 ml/kg for 30 consecutive days, and the sham operation group and the castration group are given the same amount of water.
1.3 rat body weight changes
Groups of rats were weighed and data recorded before surgery, before dosing and after dosing (week one, week two, week three and week four), respectively.
1.4 plasma hormone level determination
After the last administration, 4 ml/kg of sodium pentobarbital with the concentration of 1% is used for intraperitoneal injection anesthesia, the main artery of the abdominal cavity of a vacuum blood collection tube is used for blood collection, EDTA is used for anticoagulation, the blood is kept still for 1 h at the temperature of 4 ℃, centrifugation is carried out for 10 min at the speed of 4000 r/min, blood plasma is taken, the blood is stored in a refrigerator at the temperature of minus 20 ℃, and the detection is carried out on the next day. Determination of Folliculogenesis (FSH), Luteinization Hormone (LH), estradiol (E) in the plasma of rats of each group by radioimmunoassay2) Progesterone (P) content, kit provided by bio-pharmaceutical technology ltd, beijing betaternakang.
1.5 uterine viscera volume factor determination
After blood sampling, the uterus of the rat is taken and the surrounding adherent tissues are separated, and the weight of the uterus is weighed and recorded by an electronic analytical balance. Calculating the uterine body coefficient:
uterine body coefficient = uterine wet weight/rat body weight × 100.
1.6 data processing
The experimental data are expressed by Mean ± SD, and statistical analysis is performed on the obtained data by using SAS20.0 software, and the weight change of rats is shown in table 1 below.
TABLE 1 rat body weight changes
Note: comparison with sham group*p<0.05, comparison with model group#p<0.05。
As can be seen from Table 1 above, the body weight of the rats in the model group was significantly increased (p < 0.05) and the body weight growth of the rats was slowed down after the administration, compared to the sham-operated group, in which the dose group, the high dose group and the estradiol valerate group in the composition were significantly slowed down (p < 0.05).
FSH, LH, E in the plasma of rats of each group2And the content results of P are shown in table 2 below. As can be seen from Table 2, P and E were present in the plasma of the model group rats, as compared with the sham-operated group2The level is remarkably reduced (p)<0.01), FSH levels were significantly increased (p)<0.01) in rat plasma of each administration group compared with the model group2And P levels were uniformly elevated with some decrease in plasma FSH levels in the composition and in the high dose group rats, but none were statistically significant.
TABLE 2 plasma content of each hormone in rats
Note: comparison with sham group*p<0.01。
After castration and model building, the uterus of the rats of the model group and each administration group has different degrees of atrophy, and the specific uterus coefficient is shown in the following table 3. As can be seen from Table 3, the uterine body factor of the model group rats was significantly decreased (p < 0.01) and increased to different extents in each of the administered groups 30 days after administration, as compared with the sham-operated group, with the combination of the high dose group and estradiol valerate group being most significant (p < 0.01)
Note: comparison with sham group*p<0.01, comparison with the model surgery group#p<0.01。
The rat experiments prove that the traditional Chinese medicine components in the composition achieve the effects of nourishing yin and tonifying kidney through reasonable compatibility, so that the endocrine hormone levels are regulated, and finally the related symptoms of climacteric syndrome are relieved and improved.
Claims (6)
1. A composition for improving climacteric syndrome, which comprises the following components: prepared rehmannia root, Chinese angelica, anemarrhena, glossy privet fruit, barbary wolfberry fruit, dwarf lilyturf tuber, spina date seed and silktree albizzia flower.
2. The composition according to claim 1, characterized in that it comprises the following ingredients in parts by weight: 10-30 parts of prepared rhizome of rehmannia, 5-15 parts of angelica, 10-25 parts of rhizoma anemarrhenae, 10-25 parts of glossy privet fruit, 10-35 parts of medlar, 5-15 parts of radix ophiopogonis, 5-20 parts of spina date seed and 10-30 parts of albizia flower.
3. The composition according to claim 1, characterized in that it comprises the following ingredients in parts by weight: 12-25 parts of prepared rhizome of rehmannia, 6-12 parts of angelica, 11-20 parts of rhizoma anemarrhenae, 15-20 parts of glossy privet fruit, 11-28 parts of medlar, 5-13 parts of radix ophiopogonis, 7-15 parts of spina date seed and 10-20 parts of albizia flower.
4. The composition according to claim 1, wherein the composition for improving climacteric syndrome comprises the following components in parts by weight: 16 parts of prepared rhizome of rehmannia, 8 parts of angelica, 13 parts of rhizoma anemarrhenae, 18 parts of glossy privet fruit, 15 parts of medlar, 8 parts of dwarf lilyturf tuber, 10 parts of spina date seed and 12 parts of albizia flower.
5. A process for preparing a composition according to any one of claims 1 to 4, comprising the steps of:
1) pulverizing radix rehmanniae Preparata, radix Angelicae sinensis, rhizoma anemarrhenae and semen Ziziphi Spinosae into coarse powder, adding 10 times of 75% ethanol, extracting for 3 times, each time for 1 hr, mixing extractive solutions, filtering, and concentrating the filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of about 1.20;
2) extracting fructus Ligustri Lucidi, fructus Lycii, radix Ophiopogonis, and flos Albizziae with 10 times of water for 3 times, each for 1 hr, mixing extractive solutions, filtering, and concentrating the filtrate at 80 deg.C under reduced pressure to obtain soft extract with relative density of about 1.20;
3) mixing the above two soft extracts, drying at 80 deg.C under reduced pressure, pulverizing, adding 95% ethanol and appropriate adjuvant, making into soft mass, granulating, drying, grading, and making into granule or other dosage forms.
6. Use of the composition according to any one of claims 1 to 5 for the preparation of a health product for improving climacteric syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911392903.8A CN113117013A (en) | 2019-12-30 | 2019-12-30 | Composition for improving climacteric syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911392903.8A CN113117013A (en) | 2019-12-30 | 2019-12-30 | Composition for improving climacteric syndrome and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113117013A true CN113117013A (en) | 2021-07-16 |
Family
ID=76767477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911392903.8A Pending CN113117013A (en) | 2019-12-30 | 2019-12-30 | Composition for improving climacteric syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113117013A (en) |
-
2019
- 2019-12-30 CN CN201911392903.8A patent/CN113117013A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078520B (en) | Chinese medicinal preparation for treating nervous headache and preparation method thereof | |
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN104940509A (en) | Application of medicine composition in preparing medicine for treating gynecology hemorrhage syndrome | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN104940740A (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN102526498B (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN104258066A (en) | Traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding, and preparation method thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN104958494A (en) | Application of medicinal composition in preparation of medicament for treating gynecological hemorrhage | |
| CN115252740A (en) | Traditional Chinese medicine composition for conditioning irregular menstruation and preparation method thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN104758736A (en) | Blood-glucose-reducing traditional Chinese medicine composition and preparation method thereof | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN104306731A (en) | Traditional Chinese medicinal composition for improving deficiency symptoms of qi and blood after thyroid cancer operation | |
| CN105944020B (en) | Traditional Chinese medicine for treating ovarian function decline | |
| CN104162093A (en) | Traditional Chinese medicinal preparation for treating breast cancer, and preparation method thereof | |
| CN110237161B (en) | Medicine for treating menopausal syndrome and preparation method and application thereof | |
| CN113599475A (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN113117013A (en) | Composition for improving climacteric syndrome and preparation method thereof | |
| CN107952036B (en) | Traditional Chinese medicine preparation for reducing blood sugar and preparation method thereof | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN105311470A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210716 |